Leonard S. Schleifer, President & CEO at REGENERON PHARMACEUTICALS INC (REGN), sold 100,000 shares at $226.26 ($23.8M) on 2013-05-01, disclosed to the SEC on 2013-05-03.
Scheduled sale ($23.8M) by President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $225.01 | 20,400 | $4.6M | 19.3% |
| 2 | $226.26 | 850 | $192K | 0.8% |
| 3 | $227.40 | 500 | $114K | 0.5% |
| 4 | $228.04 | 622 | $142K | 0.6% |
| 5 | $231.18 | 5,300 | $1.2M | 5.2% |
| 6 | $232.18 | 700 |
| $163K |
| 0.7% |
| 7 | $233.34 | 5,000 | $1.2M | 4.9% |
| 8 | $235.75 | 400 | $94K | 0.4% |
| 9 | $236.47 | 3,327 | $787K | 3.3% |
| 10 | $237.31 | 2,300 | $546K | 2.3% |
| 11 | $238.65 | 3,089 | $737K | 3.1% |
| 12 | $239.68 | 4,087 | $980K | 4.1% |
| 13 | $240.44 | 7,295 | $1.8M | 7.4% |
| 14 | $241.25 | 3,350 | $808K | 3.4% |
| 15 | $242.54 | 4,695 | $1.1M | 4.8% |
| 16 | $243.41 | 11,938 | $2.9M | 12.2% |
| 17 | $244.49 | 9,814 | $2.4M | 10.1% |
| 18 | $245.55 | 5,383 | $1.3M | 5.6% |
| 19 | $246.13 | 8,700 | $2.1M | 9.0% |
| 20 | $247.32 | 450 | $111K | 0.5% |
| 21 | $248.72 | 900 | $224K | 0.9% |
| 22 | $249.45 | 600 | $150K | 0.6% |
| 23 | $250.06 | 300 | $75K | 0.3% |
| Total | $237.65 avg | 100,000 | $23.8M | 100% |
| Filing → |
| REGN | SELL | 2024-05-17 | $44.7M | — | Filing → |
| REGN | SELL | 2024-05-15 | $70.1M | — | Filing → |
| REGN | SELL | 2022-04-07 | $10.1M | — | Filing → |